Faruqi & Faruqi Achieves $385 Million Resolution for Direct Purchasers of Suboxone

New York— Faruqi & Faruqi, LLP announces that as co-lead counsel in the Suboxone Antitrust Litigation, it has achieved a $385 million settlement for a class composed of direct purchasers of Suboxone.  The 10-year litigation in the Eastern District of Pennsylvania (Philadelphia) was led by Faruqi partners Joseph Lukens and Peter Kohn.  The case alleged that the defendant, Reckitt Benckiser Pharmaceuticals, Inc., now known as Indivior, Inc., engaged in a scheme to monopolize the market for this life-saving opioid replacement therapy, causing prices to be higher by blocking less-expensive generic competitors.  The scheme allegedly included switching patients from a tablet dosage form to a film dosage form to circumvent the automatic substitution of less-expensive generic Suboxone tablets that would soon be introduced into the market.  The scheme also allegedly included a baseless petition to the FDA to slow competitor entry.  The lawsuit, filed in 2012, caught the attention of the Federal Trade Commission, several state attorneys general, and the United States Department of Justice, which empaneled a grand jury that handed down an indictment against Indivior in 2019, resulting in several guilty pleas.